Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) went up to recover about 42.57% since recording its record low price of $30. The stock experienced -2.73% slump, arriving at $42.77 on 01/11/2019. During the day, the stock price traveled from $42.65 to $44.25. This company shares are 46.13% off its target price of $62.5 and the current market capitalization stands at $2.17B. The recent change has given its price a 9.27% lead over SMA 50 and -14.55% deficit over its 52-week high. The stock witnessed 4.39% gains, 9.69% gains and -3.5% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARNA’s volatility during a week at 4.75% and during a month it has been found around 5.45%.Arena Pharmaceuticals, Inc. (ARNA) Top Holders
Institutional investors currently hold around $1.73 billion or 84.1% in ARNA stock. Look at its top three institutional owners. Wellington Management Group Llp owns $205.78 million in Arena Pharmaceuticals, Inc., which represents roughly 9.48% of the company’s market cap and approximately 11.93% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 4,756,012 shares of the stock are valued at $203.42 million. The third largest holder is Vanguard Group Inc, which currently holds $199.73 million worth of this stock and that ownership represents nearly 9.2% of its market capitalization.Arena Pharmaceuticals, Inc. 13F Filings
At the end of September reporting period, 78 institutional holders increased their position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by some 5,537,088 shares, 84 decreased positions by 5,596,966 and 27 held positions by 29,202,614. That puts total institutional holdings at 40,336,668 shares, according to SEC filings. The stock grabbed 24 new institutional investments totaling 1,660,607 shares while 27 institutional investors sold out their entire positions totaling 2,012,689 shares.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Insider Trades
Multiple company employees have indulged in significant insider trading. Arena Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP and CMO Klassen Preston has sold 19,000 shares of Arena Pharmaceuticals, Inc. (ARNA) in trading session dated Jan. 08, 2019. These shares are worth $799,140 and were traded at $42.06 each. The SEC filing shows that Spector Steven W performed a sale of 29,005 shares. The EVP, General Counsel & Sec disposed these shares by way of transaction on Aug. 15, 2018. The company’s shares were given away at $36.01 per share worth to an income of some $1,044,470 on account of Spector Steven W.
EVP, General Counsel & Sec, Spector Steven W, sold 30,001 common shares of Arena Pharmaceuticals, Inc. (ARNA) in the open market. In a transaction dated Apr. 16, 2018, the shares were put up for sale at an average price of $34.57, raking in a sum of $1,037,135. After this sale, 19,690 common shares of ARNA are directly owned by the insider, with total stake valued at $842,141.
In the transaction dated May. 12, 2017, the great number of shares acquired came courtesy the President and CEO; Munshi Amit added a total of 2,500 shares at an average price of $11.9, amounting to approximately $29,750. The insider now directly owns 7,688 shares worth $328,816.Arena Pharmaceuticals, Inc. (ARNA) Analyst Guide
Several analysts have released their opinion on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), with 3 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.78 average brokerage recommendation.